Global Trends
-
Moderna Partners with Nanexa to Extend Injectable Drug Efficacy
Moderna, the mRNA specialist, has entered a licensing agreement with Nanexa, a Swedish biotech company, to incorporate tailored release profiles…
Read More » -
Pfizer Continues Global Restructuring, Hundreds of Swiss Employees Affected by Layoffs
Pharmaceutical giant Pfizer is expanding its global cost-cutting agenda, with reports indicating that hundreds of employees in Switzerland are set…
Read More » -
Geron Pharmaceutical Corporation Implements Second Round of Workforce Reduction
Geron Corporation, the pharmaceutical company based in Foster City, California, has disclosed a substantial restructuring plan that will involve laying…
Read More » -
Pharmaceutical Firm Introduces Dual-Action Therapy for Metabolic Conditions
Cipla Limited has unveiled a new medication, known as Yurpeak, which contains the active pharmaceutical ingredient tirzepatide. This injectable treatment…
Read More » -
European Pharma Giants Sanofi and GSK Enter Preclinical Collaboration Deals
Rival European pharmaceutical companies Sanofi and GSK have both forged new partnership agreements aimed at strengthening their respective preclinical research…
Read More » -
Novartis Reports Positive Phase III Trial Data for Ianalumab in Immune Thrombocytopenia
Novartis has announced favorable outcomes from the Phase III clinical trial VAYHIT2, which assessed the efficacy of ianalumab combined with…
Read More » -
Paradigm Health Acquires Flatiron Clinical Research Arm, Raises $78M to Broaden Trial Access
Paradigm Health has completed the acquisition of Flatiron Health’s clinical research business shortly after successfully raising $78 million in a…
Read More » -
Eli Lilly Commits $6 Billion Investment for Major Pharmaceutical Manufacturing Hub in Alabama
The American pharmaceutical giant, Eli Lilly, has designated Huntsville, Alabama, as the location for its third manufacturing facility dedicated to…
Read More » -
Relation Therapeutics and Novartis Launch Collaboration to Advance Atopic Disease Therapeutics
Relation Therapeutics has announced the formation of a multi-program, strategic alliance with Novartis with the aim of accelerating the development…
Read More » -
Pfizer Accelerates Obesity Pipeline with New GLP-1 Acquisition
Licensing Agreement Details Pfizer, the U.S.-based pharmaceutical manufacturer, has signed an exclusive licensing deal with Yao Pharma—a subsidiary of Fosun…
Read More » -
Relation Therapeutics and Novartis Launch Collaboration to Advance Atopic Disease Therapeutics
Relation Therapeutics has announced the formation of a multi-program, strategic alliance with Novartis with the aim of accelerating the development…
Read More » -
Strategic Collaboration to Expand Cardiometabolic Pipeline
On December 9, 2025, a major pharmaceutical corporation based in New York announced it had entered into an exclusive global…
Read More » -
AstraZeneca’s Dual-Targeting CAR-T Shows Encouraging Efficacy
(ASH Congress) – AstraZeneca (AZ) announced positive clinical data for its leading cell therapy candidate, AZD0120 (formerly GC012F), for the…
Read More » -
Crescent and Kelun-Biotech Execute Double Deal to Swap Cancer Asset Rights
The pharmaceutical companies Crescent Biopharma (US-based) and Kelun-Biotech (China-based) have announced a strategic partnership to exchange licensing rights for two…
Read More » -
Trial Data Opens Door for Earlier Use of Lilly’s BTK Inhibitor
(ORLANDO) – At an American Society of Hematology (ASH) meeting, the pharmaceutical company Eli Lillypresented results from a critical head-to-head…
Read More » -
AstraZeneca Expands Amyloidosis Collaboration with Deal Potentially Reaching $780 Million
Alexion Pharmaceuticals, the rare disease unit of AstraZeneca, has expanded its partnership with biotech company Neurimmune by licensing a second…
Read More » -
Major Funding Deal: Therapeutics Company Secures $275 Million Through Drug Royalty Agreement
A therapeutics company has announced a funding agreement worth $275 million with a financial fund specializing in pharmaceutical royalties. The…
Read More » -
A New Breakthrough in Duchenne Muscular Dystrophy Treatment: Promising Phase 3 Trial Results
A therapeutics company has announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial, evaluating the efficacy of…
Read More » -
European Authorities Clear Novel Autoimmune Therapy for Myasthenia Gravis
The European Commission has granted authorization for nipocalimab, an immunoglobulin G (IgG) receptor antagonist developed by Johnson & Johnson, for…
Read More » -
Vetter Managing Director to Retire Following Over Three Decades of Service
Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has announced the retirement of its Managing Director, Thomas Otto,…
Read More »
